Catalyst Wire Dossier Catalyst Wire Dossier

Tuspetinib

HM43239 · Aptose Biosciences Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tuspetinib, covering 2025-08-26 to 2025-08-26. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

See pricing